Biognosys

Biognosys is a Swiss biotechnology startup focused on transforming life sciences with cutting-edge proteomics technology and solutions. Since its establishment in 2008, the company has been revolutionizing disease diagnosis, treatment, and prevention through the decoding of the proteome. Biognosys offers a versatile portfolio of proprietary proteomics services, software, and kits, catering to pharmaceutical and biotechnology researchers as well as proteomics experts. The company's mass spectrometry-based proteomics solutions enable simultaneous quantification of thousands of proteins across thousands of samples, making it a leader in next-generation proteomics. From its global headquarters just outside of Zurich, Biognosys operates one of the largest high-end mass spectrometry laboratories worldwide for Large-Scale Discovery Proteomics contract research. As of the latest available information, Biognosys has received a Series G investment as of 12 August 2019. The company's global presence is evident through its extensive network of collaborators and distributors, with employees based across Switzerland, Europe, and the US, supporting a global customer base of life science researchers across industry and academia.